Eli Lilly and Co. (LLY) said that more than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study.
The company stated that the lebrikizumab efficacy results from the trial are consistent with data in other Phase 3 studies, which further reinforces lebrikizumab's potential to be a first-line biologic treatment following topical prescription therapies for people across a range of skin tones with moderate-to-severe atopic dermatitis.
According to the company, the initial 16-week data from this study evaluated 50 patients with moderate-to-severe atopic dermatitis and darker skin tones as measured by the Fitzpatrick scale¶, including people who self-identify as Black or African American (80%), Asian (14%), American Indian or Alaska Native (6%). Of the 50 patients, 11 also self-identified as Hispanic/Latinx (22%) with the remaining 39 self-identifying as non-Hispanic/Latinx (78%). All patients received lebrikizumab 500-mg subcutaneously initially and at two weeks followed by 250-mg subcutaneously every two weeks to Week 16. Results at 16 weeks were consistent with the 16-week results from the ADhere and ADvocate 1 & 2 studies.
No new safety signals were observed and there were no serious adverse events reported. The study also included a physician assessment of changes in post-inflammatory pigmentation using the newly developed PDCA-Derm scale. Full efficacy and safety results from the study will be shared at future congresses.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.